Updates on metastatic bladder cancer from ASCO GU 2019

Bookmark and Share
Published: 15 Feb 2019
Views: 2246
Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Prof Arlene Siefker-Radtke talks about the data presented at ASCO GU 2019 and the potential impact on treatment landscape in metastatic urothelial cancer.

She highlights the abstract sessions, including exciting new information on sacituzumab and pegylated interleukin-2, as well as the potential of free circulating tumour DNA analyses.

Finally, she discusses the implications of the studies presented at ASCO GU and looks to the future for both patient outcomes and current treatment schedules.

Clinical evidence for the activity of vofatmab in patients with urothelial cancer
Therapeutic profile of gemcitabine-carboplatin vs. gemcitabine-oxaliplatin
Sacituzumab as a targeted therapy for metastatic urothelial carcinoma
Clinical activity of bempegaldesleukin
The detection of circulating free DNA in FGFR-mutant tumours
Future therapies for bladder cancer patients

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).